0001628280-26-031376
SEC filing尚未生成 AI 摘要
季报不再全量自动解析。生成研究备忘（L2/L3）或跑一次 ad-hoc 研究时，会按需补上这份文件的摘要； 在此之前请直接看 SEC 原文。
Operating cash flow (CFO) was negative at -$71.6M for the first half of FY2026, essentially flat compared to -$70.5M in the prior year. Net income was -$76.3M in 2026 versus $26.9M in 2025, but CFO was impacted by $37.4M impairment charges, $40.4M depreciation/amortization, and a $39.2M deferred tax benefit. Working capital consumed $55.1M (vs. $144.8M in 2025), partially due to the sale of the Feminine Care business.
Capital expenditures decreased to $25.6M from $33.9M, indicating reduced investment. Free cash flow (CFO minus capex) was -$97.2M, not explicitly disclosed. The primary positive cash flow driver was investing activities, which generated $315.1M mainly from the $338.9M sale of the Feminine Care segment. Financing activities used $167.4M, including $538.0M in debt repayments and $30.3M in share repurchases and dividends. The company’s cash position increased by $74.0M to $299.7M.
Anomalies: The large deferred tax benefit ($39.2M) and impairment charges ($37.4M) significantly influenced CFO. The business sale proceeds masked the underlying cash generation weakness.